# A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer

Source: https://onco.cc/trials/nct07110571/  
OnCo record `nct07110571` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Adebrelimab, Trastuzumab rezetecan and SHR-8068 in gastric & gastro-oesophageal junction cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.

## Summary

A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer is a phase 2 interventional study registered as NCT07110571 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 200 participants planned, started 2025-08-28 and due to reach its primary completion in 2026-08. Interventions recorded: Adebrelimab Injection, SHR-A1811 for Injection, SHR-A1904 for Injection and SHR-8068 Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07110571
- Phase: 2
- Setting: A Multi-cohort, Multi-center Phase II Clinical Study of Adebrelimab in Combination With SHR-A1811/SHR-A1904 and Chemotherapy or Adebrelimab in Combination With SHR-8068 as the Treatment in Subjects With Gastric or Gastroesophageal Junction Cancer
- Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Enrolled: 200

## Sources

- ClinicalTrials.gov NCT07110571: https://clinicaltrials.gov/study/NCT07110571

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [SHR-8068](https://onco.cc/drugs/shr-8068/), [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07110571.json